KBRA releases research that examines the impact of terminal reference rates at 6%, 6.5%, and 7% on its private credit assessment portfolio. In a report published in October 2022, we concluded that up to 16% of companies in a portfolio of roughly 2,000 middle market companies, all else being equal, would transition to being unable to meet interest payments from current cash flow if the terminal reference rate rises to 5.5%. The two questions we receive most frequently since the report was published are: (i) What if terminal rates rise even further, and (ii) Has stress started to materialize on the landscape of middle market borrowers, their private equity sponsors, and their private credit lenders?
In this report, we apply the higher interest rate stresses to most of the middle market private companies in our portfolio of over 2,400+ credit assessments, which are evaluations of the creditworthiness of an unrated issuer that are unpublished and confidential. In addition, we present observations from our ongoing dialogue with market participants as they grapple with the early days of a period of rising defaults and restructurings caused by higher rates, a slowing economy, and the ongoing readjustment of middle market company valuations.
Key Takeaways
A few more rate hikes do not materially change our conclusion. All-in interest costs of 12.5%-13% (terminal reference rates of 6%-6.5%) do not materially change the conclusion of our original report. While not welcome by borrowers, the prospect of a further 50 bps to 100 bps rise is not as significant compared to the movement of all-in rates from 7.5% to 12%, which is already occurring and is shaking out the most vulnerable unhedged companies. In other words, the damage is mostly done.
By comparison, some "public" companies exhibit similar strain. KBRA's revised stresses show that, once again, about 16% of roughly 2,000 mostly private middle market companies would transition to becoming unable to meet interest payments from current cash flow. But KBRA also observes that about 15% of the S&P 1500 (which includes midsize as well as large capitalization companies) are firms that have existed for at least 10 years with cash flows that have not covered their interest costs in each of the past three years.
Liquidity matters. Existing balance sheet liquidity, although getting slimmer, is helping improve some corporates' ability to make interest payments in the short term, a further reminder that companies that prioritize preserving balance sheet liquidity are better positioned to navigate a downturn in which operating cash flows get strained.
KBRA-rated structures remain resilient. Pressure on some portfolio companies is mounting due to higher interest costs and the slowing economy. This is leading to more portfolio companies on watchlists and the beginning of a period of amendments, capital infusions, and restructurings. As discussed in previous reports, KBRA continues to believe that KBRA-rated business development company (BDC), structured credit, as well as funds structures (and most lenders in these structures) remain well positioned to absorb defaults and restructurings in their portfolios.
Sponsor-backed firms with promise will de-lever if necessary. KBRA-rated lenders will generally have the upper hand in discussions with private equity sponsors and borrowers. This is primarily driven by their disciplined lending standards that ensure loan-to-value (LTV) cushions are sufficient to both absorb borrower valuation declines and/or incentivize sponsors to inject more equity?or else lose ownership of companies with still good (albeit sometimes reduced) opportunity for value creation. A failure to inject new equity into good business models can create opportunities for seasoned private credit lenders with restructuring expertise to take operating control and/or sell their stake for an attractive return.
KBRA is a full-service credit rating agency registered in the U.S., the EU, and the UK, and is designated to provide structured finance ratings in Canada. KBRA's ratings can be used by investors for regulatory capital purposes in multiple jurisdictions.
'Companion Diagnostics: Technologies and Markets' is all about using special tests alongside certain medicines to figure out which treatment will work best for each person. These tests are called companion diagnostics because they go together with...
Allied Market Research published a report, titled, "Forex Brokers Market by Counterparty (Reporting Dealers, Financial Institutions, and Non-financial Customers) and Type (Currency Swap, Outright Forward &...
Phoenix Motor Inc. , a leading manufacturer of heavy-duty transit buses and electrification solutions provider for medium-duty vehicles, today announced it will host a conference call on Thursday, May 23, 2024 at 4:30 p.m. ET to discuss and answer...
Whitman-Walker Institute, which leverages research, policy, and education to advance health equity nationwide, says it's standing by to further inform the chair of the U.S. House Committee on Education and the Workforce and others about the strong...